atrasentan has been researched along with calcitriol in 3 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (calcitriol) | Trials (calcitriol) | Recent Studies (post-2010) (calcitriol) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 16,107 | 1,224 | 3,710 |
| Protein | Taxonomy | atrasentan (IC50) | calcitriol (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0093 | |
| Vitamin D3 receptor | Homo sapiens (human) | 0.3401 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.0093 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Tan, W | 1 |
| Becker, M; Börgermann, C; Hess, J; Rübben, H; Schenck, M; Vom Dorp, F | 1 |
1 review(s) available for atrasentan and calcitriol
| Article | Year |
|---|---|
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
2 other study(ies) available for atrasentan and calcitriol
| Article | Year |
|---|---|
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
[Value of targeted therapy for prostate cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Atrasentan; Calcitriol; Drug Delivery Systems; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrrolidines; Sirolimus; Survival Rate; Thionucleotides | 2008 |